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and 2005-06 National Ambulatory Medical Care Survey and the outpatient depart-
ment component of the National Hospital Ambulatory Medical Care Survey was
conducted to examine maternal characteristics and physician characteristics as-
sociated with Category D and X prescriptions. Descriptive statistics and logistic
regression analysis were performed to determine the time trend and predictors
associated with prescribing category D and X drugs. RESULTS: Approximately 35
million visits weremade by pregnantwomen annually during these years. Of these
visits, 1.4% (95%Confidence Interval (CI):1.13-1.77%) of the visits involved prescrip-
tion of Category D drugs and 1.1% (CI:0.6-1.4%) of the visits involved prescription of
Category X drugs. A significant positive time trend was observed in prescribing of
category D and X drugs in 2005-06 (OR-2.14, 95%CI:1.23-3.73) compared to 1997-98.
Pregnant women above the age of 30 had greater odds (OR-1.62, 95%CI:1.08-2.44) of
receiving these drugs than pregnant women below the age of 30. Pregnant women
who received 2 medications had greater odds (OR-15.31,95%CI:9.02-26.01) of re-
ceiving these drugs than who received 1 medication. Significant differences
across physician specialty and race were also observed. CONCLUSIONS: Both ma-
ternal and physician characteristics play a role in prescribing of Category D and X
drugs. With increase in use of category D and X drugs, more research is needed to
evaluate the clinical consequences of these prescribing practices.
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OBJECTIVES: To determine the association between quality of hospital care, using
selected Assessing Care of Vulnerable Elders (ACOVE) quality indicators, and short
term outcomes for very old patients admitted for acute illnesses in a tertiary
hospital.METHODS: This is a retrospective review of medical records of a random
sample of all patients aged 80 years and above admitted to the Department of
General Medicine and Department of Geriatric Medicine from 2005 to 2008, with an
equal number of cases (750) selected for each year. The quality indicators selected
were cognitive and functional assessment, discharge planning, delirium evalua-
tion and treatment, mobilization, and aspiration precautions. If patients met the
inclusion criteria for each specific quality indicator, they were assessed to deter-
mine if the process-of-care was carried out and documented. The outcomes of
interest were inhospital mortality, 30-day mortality and hospital readmission
within 15 days of discharge. RESULTS: From the review of 2,923 cases, the adher-
ence for the quality indicators ranged from 33.8% for cognitive and functional
assessment to 88.1% for discharge planning. In univariate analyses, adherence to
delirium evaluation and treatment was associated with a reduction in inhospital
(17.5% vs 26.1%, p0.004) and 30-day mortality rates (22.6% vs 32.5%, p0.002).
Documentation of cognitive and functional assessment was associated with a re-
duction in inhospital (6.2% vs 16.2%, p0.005) and 30-day mortality rates (10.3% vs
22.3%, p0.005). The association between adherence to quality indicators and hos-
pital readmission was not statistically significant. After adjustments using the
biovariate probit regression, adherence to aspiration precautions was associated
with lower inhospital mortality (rho-0.128 (95% Confidence Interval:
0.233,-0.021). CONCLUSIONS: Adherence to selected process-of-care quality in-
dicatorswas generally low. Adherence to aspiration precautionswas the only qual-
ity indicator that had an impact on the short term outcome for elderly patients
hospitalized for acute medical conditions.
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OBJECTIVES: CIGNA’s CoachRx pharmacymanagement programprovides services
to pharmacy customers with medication adherence and/or medication safety is-
sues/concerns. In this study, telephonic engagement with a CoachRx pharmacist
initiated the process. The aim of this analysis was to evaluate the effect of the
CoachRx program onmedication adherence; use of mail-order pharmacy services;
utilization of generic, preferred, and non-preferred-brand medications; and ingre-
dient costs. METHODS: A pre/post comparison spanning one year (6mo pre/6mo
post) was conducted. Adherence was measured at the customer level. Continu-
ously enrolled individuals were identified, and the following demographic infor-
mation was collected: age, sex, and employer. Medication possession ratio was
used to measure adherence for five classes of medications: asthma, depression,
diabetes, dyslipidemia, and hypertension. Use of mail order pharmacy products,
gaps-in-caremeasures, and patient-requested, targetedmedication switches were
evaluated at the medication level. RESULTS: Across the classes of medications,
four of the five showed an increase in adherence following enrollment in CoachRx.
Among the customer subgroup sub-optimally adherent (MPR  80%) prior to en-
rolling in CoachRx, there was a statistically significant increase in adherence for all
five medication classes. Compliance to adherence related gaps-in-care increased
by 4% and the number of treatments filled solely through mail-order pharmacy
increased by 11% following enrollment. There was a 14.4% decrease in the share of
non-preferred brand medications, with no change in preferred brand medications
and a 2.2% increase in generic medications. Among the study participants, there
were 40 confirmed patient-requested switches from targetedmedications, with an
average ingredient cost savings of $661 per switch per year. CONCLUSIONS: The
main goal of CoachRx, to drive appropriate use of pharmacotherapy, was achieved
in the six-month, post-enrollment period. Improvement in care over such a short
period is a positive finding. These improvementsmay have an even greater impact
on futuremedical costs andmay lead to continued reductions inmedication costs.
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) has identified
several preventable adverse events, known as hospital-acquired conditions
(HACs), that in most cases CMS will not allow additional reimbursement to hospi-
tals. HACs are common or costly conditions that are acquired during the hospital
stay and could have been prevented through the application of evidence-based
guidelines. CMS has identified ten categories of HACs that are deemed to be pre-
ventable causes of morbidity and mortality. The objective of this study was to
document the prevalence of HACs for all-payers and to differentiate the impact of
HACs by payer and age group. METHODS: The study design was a retrospective
cohort from the 2008 Healthcare Cost andUtilization Project (HCUP) State Inpatient
Databases (SID) files. We used the CMS definition to identify HACs from the pres-
ent-on-admission (POA) indicator associated with secondary diagnoses in the SID.
The SID are the only multi-state all-payer data available that include the POA
indicator needed to identify HACs. We studied adult, non-maternal, medical-sur-
gical or selected surgical discharges, depending on the HAC, from community,
non-rehabilitation hospitals in fifteen states that reported POA indicators to HCUP.
RESULTS: Falls or trauma was the most prevalent HAC in our sample. For selected
surgical procedures, deep vein thrombosis/pulmonary embolism had the highest
rate of HACs (832 per 100,000 hip or knee replacement discharges). Medicaid dis-
charges had about twice the rate of manifestations of poor glycemic control and
more than twice the rate of selected surgical site infections relative to Medicare
discharges. For the conditions of stage III and IV pressure ulcers, falls and trauma,
catheter-associated urinary tract infection, and deep vein thrombosis/pulmonary
embolism the relative risk of acquiring a HAC increased with age. CONCLUSIONS:
The rate of HACs differed by payer and age group. Thus, it is important to consider
examining HACs by all third-party payers.
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OBJECTIVES:The objective of this researchwas to review the extent towhichHRQL
and other PROs have played a role in drug approval and labeling since the FDA
issued its draft guidance on the use of PRO measures and the EMA, its reflection
paper on HRQL in 2006. METHODS: This research was conducted through a sys-
tematic manual review of therapy area-specific regulatory guidelines (US and EU)
and product labelings issued during the period of January 1, 2006 to November 16,
2010. RESULTS: Fifteen and 34 guidance documents were released by the FDA and
the EMA respectively, containing recommendations for the inclusion of PRO end-
points in clinical trials. The FDA referred toHRQL (as a secondary endpoint) in three
of the 15 (20%) guidance. The EMA recommended use of HRQL endpoints in 22 of
the 34 (65%) guidance. The FDA approved 93 products with label claims that in-
cluded PRO endpoints (out of 432 total approvals). Of those, 8 products (8.6% of all
products with a PRO claim) documented treatment benefits characterized as HRQL.
The EMA approved 54 products that included PRO endpoints (out of 248 total ap-
provals), of which 16 products (29.62% of all products with a PRO claim) reflected
HRQL data. CONCLUSIONS: Our review showed that patients‘ perspective in clin-
ical research is important for the EMA and FDA, with HRQL endpoints still playing
a minor role. Our analysis suggests that EMA’s receptivity to HRQL endpoints is
greater than FDA’s,more sensitive to patient symptoms-based data. For the future,
we believe that patients’ involvement should be extended to get a more precise
idea of the PROs relevant to them. Other key players involved in reimbursement
and pricing decisions might have their say since financial health resources will
become scarce and that assessing value for money will be more crucial.
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OBJECTIVES: On March 23, 2010 the Patient Protection and Affordable Care Act
(PPACA) was signed into a law providing health insurance coverage for approxi-
mately 32million uninsuredAmericans. The objective is to determine the expected
changes in health care utilization for the uninsured after 2014when key provisions
of PPACA law become effective.METHODS:Medical Expenditure Panel Survey data
(2008) was used for the analysis. The differences in health care utilization between
the uninsured and those with private or Medicaid coverage was estimated using a
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